慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化

doi:10.3969/j.issn.1672-5069.2021.03.006

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (3): 327-330.doi: 10.3969/j.issn.1672-5069.2021.03.006

慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化

林列坤, 卢春生, 周应生, 郑义, 杨菊红, 邹继彬, 张仁超, 梁旭竞

518106 广东省深圳市中国科学院大学深圳医院医学遗传与分子诊断中心(林列坤,卢春生,郑义,杨菊红);
消化内科(周应生);
病理科(邹继彬,张仁超);
中山大学附属第七医院感染病科(梁旭竞)

收稿日期:2020-07-09 出版日期:2021-05-30 发布日期:2021-04-30
作者简介:林列坤,女,48岁,大学本科,副主任技师,遗传咨询师。研究方向:从事产前生化免疫和分子基因诊断研究。E-mail:2731313958@qq.com
基金资助:
深圳市科技计划项目(编号:JCYJ20170307093622283)

Changes of histone deacetylase mRNA levels after histone acetylation inhibitor management in liver tissue of mice with acute-on-chronic liver failure

Lin Liekun, Lu Chunsheng, Zhou Yingsheng, et al

The Center of Medical Genetics and Molecular Diagnosis, Shenzhen Hospital,University of Chinese Academy of Sciences, Shenzhen 518106,Guangdong Province,China

Received:2020-07-09 Online:2021-05-30 Published:2021-04-30

摘要/Abstract

摘要： 目的探讨组蛋白去乙酰化酶(HDAC) 抑制剂干预慢加急性肝衰竭(ACLF)小鼠肝组织组蛋白去乙酰化酶mRNA水平变化。方法随机将小鼠分为7组,每组4只。A组为对照组,B组为模型组,C组为曲古抑菌素 A(TSA)处理组,D组为大剂量正丁酸钠处理组,E组为小剂量正丁酸钠处理组,F组为大剂量吡咯烷二硫代氨基甲酸(PDTC)处理组,G组为小剂量PDTC处理组,采用脂多糖联合D-Gal诱导小鼠肝衰竭模型。采用Q-PCR法检测小鼠肝组织Ⅰ类和Ⅱ类HDAC mRNA水平。结果 B组肝组织HDAC1mRNA、HDAC2mRNA、HDAC3mRNA和HDAC8mRNA水平分别为(1.7±0.2)、(1.7±0.3)、(1.9±0.6)和(2.6±0.7),而C组、D组、E组、F组和G组均显著降低(P<0.05);B组肝组织HDAC4mRNA、HDAC5mRNA、HDAC6mRNA、HDAC7mRNA、HDAC9mRNA和HDAC10mRNA水平分别为(0.6±0.2)、(6.3±0.9)、(3.4±0.8)、(2.8±1.0)、(6.5±1.1)和(0.4±0.1),而C组、D组、E组、F组和G组均显著降低(P<0.05)。结论 HDAC mRNA水平可能与机体乙酰化作用相关,可为应用组蛋白乙酰化调控治疗肝衰竭小鼠提供重要的理论依据。

关键词: 肝衰竭, 组蛋白去乙酰化酶, 曲古抑菌素 A, 正丁酸钠, 吡咯烷二硫代氨基甲酸, 小鼠

Abstract: Objective The aim of this study was to study the changes of histone deacetylase mRNA levels after histone acetylation (HDAC) inhibitor intervention in liver tissue of mice with acute-on-chronic liver failure (ACLF).Methods 28 mice were randomly divided into seven group, with four in each, and the liver failure was induced in mice by lipopolysaccharide (LPS) and D-Gal injection. The mice in group A (control), B (model), C, D, E, F and G were intervened by normal saline, normal saline, trichostatin A(TSA), large dose of sodium butyrate, low dose of sodium butyrate, large dose of pyrrolidine dithiocarbarmate (PDTC) and low dose of PDTC, respectively. The hepatic HDAC mRNA was assayed by Q-PCR.Results The hepatic HDAC1mRNA, HDAC2mRNA, HDAC3mRNA and HDAC8mRNA in group B were (1.7±0.2), (1.7±0.3), (1.9±0.6) and (2.6±0.7), while all of them in group C, group D, group E, group F and group G decreased greatly (P<0.05); the hepatic HDAC4mRNA, HDAC5mRNA, HDAC6mRNA, HDAC7mRNA, HDAC9mRNA and HDAC10mRNA in group B were (0.6±0.2),(6.3±0.9),(3.4±0.8),(2.8±1.0),(6.5±1.1) and (0.4±0.1), while all of them in group C, group D, group E, group F and group G decreased significantly as compared to those in group B(P<0.05).Conclusion The hepatic HDAC mRNA levels is related to the acetylation of proteins, which might reinforce the theoretical basis for the application of histone acetylation regulation in Dealing withliver failure in mice.

Key words: Acute-on-chronic liver failure, Histone deacetylase, Trichostatin A, Sodium butyrate, Pyrrolidine dithiocarbarmate, Mice

林列坤, 卢春生, 周应生, 郑义, 杨菊红, 邹继彬, 张仁超, 梁旭竞. 慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(3): 327-330.

Lin Liekun, Lu Chunsheng, Zhou Yingsheng, et al. Changes of histone deacetylase mRNA levels after histone acetylation inhibitor management in liver tissue of mice with acute-on-chronic liver failure[J]. Journal of Practical Hepatology, 2021, 24(3): 327-330.

参考文献

[1] 李异,田沂,陈军,等.乙型肝炎相关性慢加急性肝衰竭的治疗策略.中华临床医师杂志(电子版),2015,9(10):1774-1777.
[2]中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018 年版). 实用肝脏病杂志,2019,22(2): 164-171.
[3] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology, 2013, 144 (7):1426-1437.
[4] Barretor H, Fagundesc JG,Guevaram HA,et a1.Type-l hepatorenal syndrome associated with infections in cirrhosis:natural history,outcome of kidney function,and survival.Hepatology,2014,59(4):1505-1513.
[5] Sozinov AS. Systemic endotoxemia during chronic viral hepatitis. Bull Exp Biol Med, 2002, 133(2): 153-155.
[6] 王瑶,龚作炯.肝衰竭过程中乙酰化调控和细胞焦亡.世界华人消化杂志,2018,26(11):633-638+630.
[7] Zhang Q,Yang F,Li X,et a1.Trichostatin ainhibits inflammation in phorbol myristate acetate-induced macrophages by regulating the acetylation of histone and／or non—histone proteins.Mol Med Rep, 2016,13(1):845-852.
[8] Steetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000, 119(2): 446-460.
[9] 李晓东,徐东平.HBV相关慢加急性肝衰竭免疫病理发病机制研究进展.实用肝脏病杂志,2015,18(3):317-320.
[10] Hu YY, Dai JJ, Zong GZ, et al. Restoration of p53 acetylation by HDAC inhibition permits the necrosis/apoptosis switch of pancreatic ainar cell during experimental pancreatitis in mice. J Cell Physiol, 2019, 234(12):21988-21998.
[11] Marumo T,Hishikawa K,Yoshikawa M,et al. Histone deacetylase modulates the proinflammatory and fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol, 2010,298(1): 133-141.
[12] Sarin SK,Choudhury A. Acute-on-chronic liver failure: terminology,mechanisms and management. Nat Rev Gastroenterol Hepatol,2016, 13(3):131-149.
[13] Monneret C. Histone deacetylase inhibitors. Eur J Med Chem,2005,40: 1-13.
[14] Chrun ES, Modolo F, Daniel FI. Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathol Res Pract , 2017, 213: 1329-1339.
[15] 张海月,李汛,张倩,等.MS-275对急性肝衰竭小鼠肝脏的保护作用.中华临床感染病杂志,2016,9(4):349-354.
[16] Cantley MD, Zannettino ACW, Bartold PM, et al. Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone,2017, 95: 162-174.
[17] Zhang L, Wan J, Jiang R, et al. Protective effects of trichostatin A on liver injury in septic mice. Hepatol Res, 2009, 39(9): 931-938.
[18] Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med, 2005, 11(1/12):1-15.

慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化

Changes of histone deacetylase mRNA levels after histone acetylation inhibitor management in liver tissue of mice with acute-on-chronic liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭婕, 李弼民, 雷宇鹏. 四氯化碳诱导的肝纤维化小鼠肝组织和HSC-T6细胞NOX4基因及其蛋白表达的变化[J]. 实用肝脏病杂志, 2021, 24(3): 319-322.
[2]	王丽惠, 张佳祥, 刘双平, 张惠勇, 卢秋燕, 沈培根. 原儿茶酸对刀豆蛋白A所致的免疫性肝损伤小鼠肝组织MDA、NO、SOD和GSH-PX表达的影响[J]. 实用肝脏病杂志, 2021, 24(3): 323-326.
[3]	刘松涛, 孟庆华, 闾军, 刘梅, 许媛, 周建新, 胡中杰. 淋巴瘤化疗诱发肝衰竭患者临床特点与预后分析[J]. 实用肝脏病杂志, 2021, 24(3): 383-386.
[4]	孔雪杰, 李江, 李昊天, 李绪桐, 郜玉峰. 不同肝病基础的慢加急性肝衰竭患者临床特征和预后评分模型预测效能比较[J]. 实用肝脏病杂志, 2021, 24(3): 387-390.
[5]	苏亚勇, 徐成润, 郭永木, 张惠勇, 刘双平, 陈小兰. 慢加急性乙型肝炎肝衰竭患者死亡危险因素和预后评分模型的构建[J]. 实用肝脏病杂志, 2021, 24(3): 391-394.
[6]	党玲, 贾皑, 王芳. 血清内毒素结合蛋白和sCD163水平预测亚急性肝衰竭患者预后的价值分析[J]. 实用肝脏病杂志, 2021, 24(3): 447-448.
[7]	都庆国, 陆建文, 王建华, 龙延滨, 薛飞. 生长抑素通过抑制内质网应激反应减轻肝纤维化小鼠肝损伤研究[J]. 实用肝脏病杂志, 2021, 24(2): 172-175.
[8]	魏荣荣, 李爱玲, 李红, 张缭云. 慢性肝炎肝硬化和肝衰竭患者吲哚菁绿清除试验的变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 91-94.
[9]	黄鹤鸣, 刘彦君, 付荣, 石催催, 范建高, 张元元, 罗成, 李光明. BET抑制剂(+)-JQ1通过调节NF-KB信号通路保护小鼠急性肝衰竭实验研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 781-784.
[10]	关万涛, 康福新, 林维, 林宏云, 黎仕焕. CRRT联合PE治疗慢加急性乙型肝炎肝衰竭并发急性肾损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 833-836.
[11]	王培, 张青, 李颍, 颜学兵, 丁芹. 基于红细胞分布宽度和中性粒细胞/淋巴细胞比值建立慢加急性乙型肝炎肝衰竭患者短期预后预测模型价值研究[J]. 实用肝脏病杂志, 2020, 23(5): 682-686.
[12]	董静, 刘龙梅, 陈照林, 陈曦, 宋海燕, 吕荣德, 张骏飞, 刘波. 富马酸替诺福韦二吡呋酯联合双重血浆分子吸附系统序贯血浆置换治疗慢加急性乙型肝炎肝衰竭患者疗效分析[J]. 实用肝脏病杂志, 2020, 23(5): 687-690.
[13]	陈煜. 再论慢加急性肝衰竭新的临床分型及临床意义[J]. 实用肝脏病杂志, 2020, 23(4): 457-458.
[14]	李侗曾, 孔明, 宋文艳, 徐曼曼, 陈煜, 全国疑难及重症肝病攻关协作组. 慢加急性肝衰竭患者第三腰椎骨骼肌指数与临床指标的关系^*[J]. 实用肝脏病杂志, 2020, 23(4): 467-470.
[15]	陈曦, 陈照林, 董静, 宋海燕, 刘波, 张骏飞, 陈从新. 脐带间充质干细胞联合双重血浆分子吸附治疗慢加急性肝衰竭患者临床效果初步观察[J]. 实用肝脏病杂志, 2020, 23(4): 544-547.